ABSTRACT Introduction: Carbonic anhydrase inhibitors (CAIs) have been in clinical use for decades for the management of various disorders. An update on their drug–drug interactions is presented here considering these main therapeutic areas and drugs: glaucoma (acetazolamide, methazolamide, dichlorophenamide, dorzolamide, and brinzolamide); epilepsy/obesity (sulthiame, topiramate, and zonisamide); arthritis/inflammation (celecoxib and polmacoxib) and hypoxic tumors (SLC-0111). Areas covered: Drug interactions reported between CAIs with various other pharmacological agents are reviewed in publications after 2016, when the previous review was published. Most reported interactions concern the antiepileptics sulthiame, topiramate, and zonisamide, as they are part of complex regimens in which drugs controlling this disorder are administered. Fewer interactions were reported for the anti-glaucoma agents, whereas synergistic combinations of celecoxib with antibiotics or SLC-0111 with various antitumor drugs were extensively investigated. Expert opinion: Drug interactions involving CAIs may be used both for monitoring the clinical efficacy of these agents when co-administered with other drugs but also for better controlling some diseases, such as hypoxic tumors, case for which the combination of CAIs with other anticancer agents (histone deacetylase inhibitors, alkylating agents, antimetabolite nucleosides, angiogenesis inhibitors, and immune checkpoint inhibitors) proved to be synergistic.

中文翻译：

---

碳酸酐酶抑制剂治疗应用中药物相互作用考虑的更新

摘要 介绍：碳酸酐酶抑制剂 (CAI) 几十年来一直用于临床治疗各种疾病。考虑到以下主要治疗领域和药物，此处介绍了它们的药物相互作用的最新情况：青光眼（乙酰唑胺、甲唑胺、二氯苯甲酰胺、多佐胺和布林佐胺）；癫痫/肥胖症（磺胺嘧啶、托吡酯和唑尼沙胺）；关节炎/炎症（塞来昔布和泊马考昔）和缺氧肿瘤（SLC-0111）。涵盖的领域：在 2016 年之后的出版物中对 CAI 与各种其他药物制剂之间报告的药物相互作用进行了审查，当时上一次审查发表。大多数报道的相互作用与抗癫痫药磺胺嘧啶、托吡酯和唑尼沙胺有关，因为它们是控制这种疾病的药物的复杂治疗方案的一部分。抗青光眼药物的相互作用较少，而塞来昔布与抗生素或 SLC-0111 与各种抗肿瘤药物的协同组合得到了广泛研究。专家意见：涉及 CAIs 的药物相互作用既可用于监测这些药物与其他药物合用时的临床疗效，也可用于更好地控制某些疾病，例如缺氧性肿瘤，在这种情况下，CAI 与其他抗癌药物联合使用（组蛋白去乙酰化酶抑制剂、烷化剂、抗代谢物核苷、血管生成抑制剂和免疫检查点抑制剂）被证明具有协同作用。